Merck & Co., Inc. Q3 2025 Earnings Recap

MRK Q3 2025 October 31, 2025

Get alerts when MRK reports next quarter

Merck & Co. reported solid third-quarter performance, marked by significant pipeline advancements and successful new product launches, including the FDA approval of KEYTRUDA QLEX. The company also strengthened its growth trajectory through a strategic acquisition and robust investment plans in U.S. manufacturing.

Earnings Per Share Beat

$2.58 vs $2.36 est.

+9.3% surprise

Revenue Beat

17276000000 vs 16978146374 est.

+1.8% surprise

Market Reaction

1-Day -4.06%

5-Day +0.35%

30-Day +18.95%

See MRK alongside your other holdings

Add to your portfolio — free

Key Takeaways

Revenue growth driven by strong performance in Oncology and Animal Health, with new product launches making increasing contributions.
Completion of the strategic acquisition of Verona Pharma, enhancing Merck’s growth potential with multibillion-dollar opportunities.
Positive Phase III trial results in cardiovascular research and successful FDA approvals for WINREVAIR and KEYTRUDA QLEX, expanding treatment options in key therapeutic areas.
Commitment to investing over $70 billion in U.S. manufacturing and R&D to support long-term growth and innovation.
Ongoing focus on strategic business development to further diversify and enhance the company's pipeline and commercial portfolio.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit MRK on AllInvestView.

Previous Q2 2025

Next Q1 2026